Our work maps the molecular components of prevalent women’s health issues to create novel tests for quicker diagnosis and better outcomes.
With our first product, DotEndo, earlier detection and treatment of endometriosis will be possible.
DotEndo is a breakthrough blood test that analyzes the expression of microRNA biomarkers associated with the endometriosis to provide a clear positive or negative result, not a risk profile.
DotEndo was developed based on over a decade of peer-reviewed scientific research and development, demonstrating the association of microRNAs to endometriosis and infertility.
Accurate Diagnosis of Endometriosis Using Serum MicroRNAs (2020)
This study, published in the American Journal of Obstetrics and Gynecology, is the first peer-reviewed publication showing biomarkers that can reliably differentiate between endometriosis and other gynecologic pathologies with high accuracy.
Serum microRNAs as diagnostic markers of endometriosis: a comprehensive array-based analysis (2016)Learn more
Circulating microRNAs as potential biomarkers for endometriosis (2015)Learn more
The EMPOWER Study is a prospective, observational, multi-center study intended to provide additional validation for DotLab’s non-invasive test for the diagnosis of endometriosis. The study is enrolling approximately 750 women of reproductive potential aged 18-49 who have been referred to undergo laparotomy or laparoscopy or other procedures for suspected endometriosis and other benign gynecological indications.